TO THE EDITOR
Follicular lymphoma (FL) accounts for approximately 20% of malignant lymphomas. Its clinical course is characterized by a good response to initial treatment, followed by frequent relapses. When the International Prognostic Index 1 (IPI), which was originally proposed for aggressive lymphoma in 1993, is applied for patients with FL, only a small percentage of patients (20%) are classified in the high/highintermediate-risk group. 2 Therefore, IPI is not fully appropriate in predicting the prognosis of patients with FL who are considered candidates for intensive or experimental therapy. In 2004, FLIPI 2 was proposed as a more suitable prognostic index for patients with FL. It consists of 5 adverse prognostic factors : (1) age older than 60 years, (2) advanced clinical stage, (3) hemoglobin level lower than 120 g/L, (4) more than 4 nodal areas, and (5) elevated serum lactate dehydrogenase level. In 2009, FLIPI-2 3 was newly established because FLIPI was found to be inadequate because it was defined before the era of anti-CD20 monoclonal antibody treatments, such as rituximab therapy, and does not include the more recently reported parameters, such as b2 -microglobulin. 4 FLIPI-2 consists of 5 adverse prognostic factors : (1) elevated b2-microglobulin, (2) largest node involved having a diameter greater than 6 cm, (3) bone marrow involvement, (4) hemoglobin level lower than 120 g/L, and (5) age older than 60 years. In establishing the prognostic index of FLIPI-2, the end point was not set as overall survival but as progressionfree survival, reflecting the incurable characteristics of FL. However, the original reported study on FLIPI-2 involved many patients without exposure to rituximab. 3 Shortly after FLIPI was introduced, one study evaluated the predictive value of FLIPI for patients with advanced-stage FL treated with front-line immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and proved its usefulness in identifying high-risk patients. 5 Recently, another study validated the role of FLIPI-2 as a prognostic index for patients in the rituximab era. 6 In this study, we evaluated FLIPI-2 for patients with untreated FL who received initial therapy with R-CHOP.
One hundred and seven patients aged 15 or over with FL who received R-CHOP therapy between 2001 and 2009 were identified from the database of the Yokohama City University Hematology Group. This study was approved by the institutional review board of Kanagawa Cancer Center. The procedures of this study were in accordance with the Helsinki Declaration. Since 2001, the Yokohama City University Hematology Group in Japan has uniformly and curatively treated patients with FL, except those with stage 1 FL, with 6 cycles of standard R-CHOP therapy for 21 days. Patients who had partial response (PR) after the 4 initial cycles were administered a total of 8 R-CHOP cycles, whereas patients who did not achieve PR after the 4 initial R-CHOP cycles or those who exhibited disease progression at any given time received salvage therapy. In these cases, the time point to disease progression was determined. Additional local irradia-tion was also performed in patients with PR or complete response if deemed necessary by the attending physician. In our 107 patients, the presence or absence of additional radiotherapy was unknown in 2 patients. In the remaining 105 patients, 8 patients (PR in 6 and complete response [CR] in 2) received the additional radiotherapy as first-line therapy. The radiation fields were abdominal nodes in 5, cervical node in 1, axillar node in 1, and inguinal/femoral node in 1. However, only 1 CR was newly achieved in the 6 PR patients. No patients received maintenance therapy with rituximab. The presence or absence of a node with a diameter greater than 6 cm was retrospectively investigated to evaluate the efficacy of FLIPI-2.
The results of patients evaluated by FLIPI and FLIPI-2 are shown in Table 1 in terms of prognostic factors and riskgroup classification. The median age was 57 years (range, 34 to 78). Compared with the patients in the original study on FLIPI-2, 3 only 10% of our patients were classified in the lowrisk group because of the high proportion of patients with elevated serum b2-microglobulin levels (57%), with largest node involved having a diameter greater than 6 cm (46%), and with bone marrow involvement (52%). There were no correlations between the pathological grades of FL and the risk-group distribution of FLIPI and FLIPI-2 (data not shown). Compared with FLIPI (Fig. 1A) , FLIPI-2 (Fig. 1B) was more efficient for identifying three risk groups in terms of progression-free survival using log-rank test ; however, the statistical value was marginally significant (P = 0.08). The 5-year progression-free survival rates according to FLIPI-2 were 76%, 49%, and 37% in the low-, intermediate-, and high-risk patient groups, respectively. In contrast, FLIPI was somewhat more efficient in predicting overall survival of the patients in the three risk subgroups than FLIPI-2 (P = 0.009 versus P = 0.29, data not shown).
To predict the prognosis of patients with low progressionfree survival rates initially treated with R-CHOP therapy, FLIPI-2 might be more efficient, despite its marginal significance here. It is necessary to validate the efficiency of FLIPI-2 by using a large cohort of patients in the rituximab era.
